Treatment
4Thyroid cancer therapy reference (2026)
Reference snapshot of thyroid cancer therapy across differentiated, medullary, and anaplastic subtypes.
Cholangiocarcinoma therapy reference (2026)
Reference snapshot of cholangiocarcinoma therapy across resectable and advanced disease and biomarker-defined targeted tiers.
Adult diffuse glioma therapy reference (2026)
Reference snapshot of adult diffuse glioma therapy across IDH-mutant grade 2/3 disease, glioblastoma first-line, and recurrent disease.
Hepatocellular carcinoma therapy reference (2026)
Reference snapshot of HCC therapy across early, intermediate, and advanced disease.
Pipeline
2Bispecific antibody class landscape in oncology, 2026 mid-year reference
Reference layout of the bispecific antibody class in oncology as of mid-2026: approved assets across haematology and solid tumours, the T-cell engager subclass, the dual-checkpoint subclass, and the live commercial questions including site-of-care infrastructure and combination strategy.
ADC class landscape, 2026 mid-year reference
Reference layout of the antibody-drug conjugate class in oncology as of mid-2026: approved assets by target and indication, late-stage pipeline by mechanism, and the live differentiation axes the field is settling on.